NASDAQ:REPH - Recro Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.99 +0.10 (+1.27 %) (As of 01/18/2019 04:00 PM ET)Previous Close$7.89Today's Range$7.81 - $8.0252-Week Range$4.78 - $13.05Volume101,100 shsAverage Volume127,531 shsMarket Capitalization$167.95 millionP/E Ratio-4.02Dividend YieldN/ABeta-0.52 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania. Receive REPH News and Ratings via Email Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPH Previous Symbol CUSIPN/A Webwww.recropharma.com Phone484-395-2470Debt Debt-to-Equity Ratio4.04 Current Ratio1.36 Quick Ratio1.16Price-To-Earnings Trailing P/E Ratio-4.02 Forward P/E Ratio-3.00 P/E GrowthN/A Sales & Book Value Annual Sales$71.83 million Price / Sales2.39 Cash FlowN/A Price / Cash FlowN/A Book Value$1.51 per share Price / Book5.29Profitability EPS (Most Recent Fiscal Year)($1.99) Net Income$-50,080,000.00 Net Margins-79.42% Return on Equity-220.42% Return on Assets-27.96%Miscellaneous Employees256 Outstanding Shares21,477,000Market Cap$167.95 million OptionableOptionable Recro Pharma (NASDAQ:REPH) Frequently Asked Questions What is Recro Pharma's stock symbol? Recro Pharma trades on the NASDAQ under the ticker symbol "REPH." How were Recro Pharma's earnings last quarter? Recro Pharma Inc (NASDAQ:REPH) announced its quarterly earnings results on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.03. The specialty pharmaceutical company had revenue of $18.28 million for the quarter, compared to analysts' expectations of $16.77 million. Recro Pharma had a negative net margin of 79.42% and a negative return on equity of 220.42%. View Recro Pharma's Earnings History. When is Recro Pharma's next earnings date? Recro Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Recro Pharma. What guidance has Recro Pharma issued on next quarter's earnings? Recro Pharma issued an update on its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $75-75 million, compared to the consensus revenue estimate of $73.46 million. What price target have analysts set for REPH? 7 equities research analysts have issued 12-month price targets for Recro Pharma's stock. Their forecasts range from $9.00 to $19.00. On average, they expect Recro Pharma's share price to reach $13.80 in the next twelve months. This suggests a possible upside of 72.7% from the stock's current price. View Analyst Price Targets for Recro Pharma. What is the consensus analysts' recommendation for Recro Pharma? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma. Has Recro Pharma been receiving favorable news coverage? News articles about REPH stock have trended positive this week, InfoTrie reports. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Recro Pharma earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near future. Who are some of Recro Pharma's key competitors? Some companies that are related to Recro Pharma include Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), CannTrust (CNTTF), Vectura Group (VEGPF), Ra Pharmaceuticals (RARX), ANI Pharmaceuticals (ANIP), Omeros (OMER), Aurinia Pharmaceuticals (AUPH), Basilea Pharmaceutica (BPMUF), Eagle Pharmaceuticals (EGRX), ChemoCentryx (CCXI), Kura Oncology (KURA), Cara Therapeutics (CARA), Karyopharm Therapeutics (KPTI) and ProQR Therapeutics (PRQR). Who are Recro Pharma's key executives? Recro Pharma's management team includes the folowing people: Dr. Geraldine A. Henwood, CEO, Pres & Director (Age 66)Mr. Michael Celano, COO & Corp. Sec. (Age 59)Dr. Stewart McCallum, Chief Medical Officer (Age 52)Mr. Ryan D. Lake, Chief Financial Officer (Age 41)Mr. Randall J. Mack, Sr. VP of Devel. and Corp. Sec. (Age 53) Who are Recro Pharma's major shareholders? Recro Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.05%). Company insiders that own Recro Pharma stock include Healthcare Master Fun Broadfin, James E Flynn, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp and Stonepine Capital Management,. View Institutional Ownership Trends for Recro Pharma. Which institutional investors are selling Recro Pharma stock? REPH stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Recro Pharma. How do I buy shares of Recro Pharma? Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Recro Pharma's stock price today? One share of REPH stock can currently be purchased for approximately $7.99. How big of a company is Recro Pharma? Recro Pharma has a market capitalization of $167.95 million and generates $71.83 million in revenue each year. The specialty pharmaceutical company earns $-50,080,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Recro Pharma employs 256 workers across the globe. What is Recro Pharma's official website? The official website for Recro Pharma is http://www.recropharma.com. How can I contact Recro Pharma? Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected] MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 247 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 451MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: Why do corrections happen?